HC Wainwright Has Negative Outlook for PolyPid Q3 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for PolyPid in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.39) for the quarter, down from their previous forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $1.46 EPS.

Several other brokerages have also issued reports on PYPD. JMP Securities cut their price objective on PolyPid from $16.00 to $14.00 and set a “market outperform” rating for the company in a report on Tuesday, June 17th. Wall Street Zen lowered PolyPid from a “hold” rating to a “sell” rating in a report on Saturday. Roth Capital reiterated a “buy” rating on shares of PolyPid in a report on Thursday. Finally, Craig Hallum reiterated a “buy” rating and set a $13.00 price objective (down from $15.00) on shares of PolyPid in a report on Thursday. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.40.

PolyPid Trading Up 0.6%

Shares of NASDAQ:PYPD opened at $3.45 on Friday. PolyPid has a 1 year low of $2.30 and a 1 year high of $3.93. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $3.06. The firm has a market cap of $54.86 million, a price-to-earnings ratio of -0.90 and a beta of 1.40.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, August 13th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.25).

Hedge Funds Weigh In On PolyPid

Several institutional investors have recently bought and sold shares of PYPD. AIGH Capital Management LLC raised its holdings in PolyPid by 27.0% during the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after buying an additional 253,727 shares in the last quarter. J. Goldman & Co LP bought a new position in PolyPid during the fourth quarter valued at about $391,000. Finally, Lumbard & Kellner LLC bought a new position in PolyPid during the second quarter valued at about $135,000. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.